Celltrion, Inc. (KRX:068270)
South Korea · Delayed Price · Currency is KRW | Market Cap | 38.64T |
| Revenue (ttm) | 3.75T |
| Net Income (ttm) | 492.08B |
| Shares Out | 220.30M |
| EPS (ttm) | 2,199.34 |
| PE Ratio | 79.75 |
| Forward PE | 35.85 |
| Dividend | 686.81 (0.39%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 558,334 |
| Average Volume | 532,064 |
| Open | 175,400 |
| Previous Close | 175,100 |
| Day's Range | 174,300 - 177,000 |
| 52-Week Range | 144,615 - 188,800 |
| Beta | 0.41 |
| RSI | 52.95 |
| Earnings Date | Nov 5, 2025 |
About Celltrion
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bo... [Read more]
Financial Performance
In 2024, Celltrion's revenue was 3.56 trillion, an increase of 63.45% compared to the previous year's 2.18 trillion. Earnings were 422.69 billion, a decrease of -21.09%.
Financial StatementsNews
Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal
Asian drug stocks faced a downturn. This followed US President Trump's tariff threat on imported pharmaceuticals. South Korean and Japanese drugmakers experienced declines. Samsung Biologics and Sumit...
Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence
Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence
South Korea's Celltrion unit buys Eli Lilly's production facility for $330M
Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value
Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing ...
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager | ABP Stock News
Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement
Shilpa Medicare Limited has entered into a settlement agreement with Celltrion Inc., a South Korea-based pharmaceutical company, thereby resolving an ongoing arbitration dispute. The company informed ...
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
Remdantry™ (previously known as Inflectra®), developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar infliximab in Canada and will be commercially available across Canada ...
Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian mark...
FDA approves Celltrion's biosimilar of J&J's Stelara
Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada
Omlyclo™ (CT-P39) is the first and only omalizumab biosimilar referencing Xolair® approved in Canada to treat multiple allergic diseases including chronic idiopathic urticaria (CIU), allergic asthma, ...